<html lang="en"><meta name="viewport" content="width=device-width, initial-scale=1" /><head><link rel="stylesheet" href="../init.css"><title>Does the Medline mega-deal herald the return of giant buyouts?</title></head><body><div class="ds-layout-grid ds-layout-grid--edged layout-article-header"><div class="article__lead-image" data-test-id="Lead Image"><div itemprop="image" itemscope="" itemtype="https://schema.org/ImageObject"><meta content="https://www.economist.com/img/b/1280/720/90/sites/default/files/images/2021/06/articles/main/20210612_wbp501.jpg" itemprop="url"/><img alt="" height="720" sizes="(min-width: 1440px) 940px, (min-width: 1080px) 75vw, (min-width: 960px) 90vw, (min-width: 800px) 720px, 95vw" src="../image/20210612_wbp501.jpg" srcset="../image/20210612_wbp501.jpg" width="1280"/></div></div><header class="article__header"><h1><span class="article__subheadline" data-test-id="Article Subheadline">Dealing with abundance</span><br/><span class="article__headline" data-test-id="Article Headline" itemprop="headline">Does the Medline mega-deal herald the return of giant buyouts?</span></h1><h2 class="article__description" data-test-id="Article Description" itemprop="description">Private-equity firms are neck-deep in dry powder</h2></header><script type="application/ld+json">
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"https://www.economist.com/business/","name":"Business"}},{"@type":"ListItem","position":2,"item":{"@id":"https://www.economist.com/printedition/2021-06-12","name":"Jun 12th 2021 edition"}}]}
</script><div class="article__section"><strong itemprop="articleSection"><span class="article__section-headline"><a href="/business/">Business</a></span></strong><a class="article__section-edition" data-test-id="Article Datetime" href="/printedition/2021-06-12"><span>Jun 12th 2021<!-- --> edition</span></a></div><hr class="ds-rule layout-article-header__rule"/><div class="advert right hidden advert--right-rail" id=""><div><div id="econright-r0"></div></div></div></div><div class="ds-layout-grid ds-layout-grid--edged layout-article-body" itemprop="text"><div class="layout-sticky-rail"><div class="layout-sticky-rail-advert-wrapper"><div class="advert right hidden advert--right-rail advert--sticky-rail" id=""><div><div id="econright-r1"></div></div></div></div></div><p class="article__body-text article__body-text--dropcap" data-caps="initial"><span data-caps="initial"></span></p><div class="article-audio-player"><figure class="article-audio-player__figure"><figcaption>Listen to this story</figcaption><audio class="react-audio-player" controls="" controlslist="nodownload" id="audio-player" preload="none" src="../audio/does-the-medline-mega-deal-herald-the-return-of-giant-buyouts.mp3" title="Does the Medline mega-deal herald the return of giant buyouts?"><p>Your browser does not support the &lt;audio&gt; element.</p></audio></figure><p class="article-audio-player__cta">Enjoy more audio and podcasts on<!-- --> <a href="https://apps.apple.com/app/apple-store/id1239397626?pt=344884&amp;ct=article%20audio%20player&amp;mt=8" id="audio-ios-cta" rel="noreferrer" target="_blank">iOS</a> <!-- -->or<!-- --> <a href="https://play.google.com/store/apps/details?id=com.economist.lamarr&amp;referrer=utm_source%3Darticle%2520audio%2520player" id="audio-android-cta" rel="noreferrer" target="_blank">Android</a>.</p></div><figure><div data-slim="0" itemprop="image" itemscope="" itemtype="https://schema.org/ImageObject"><meta content="https://www.economist.com/img/b/1280/769/90/sites/default/files/images/print-edition/20210612_WBC546.png" itemprop="url"/><img alt="" loading="lazy" sizes="(min-width: 720px) 640px, 95vw" src="../image/20210612_WBC546.png" srcset="../image/20210612_WBC546.png"/></div></figure><p class="article__body-text article__body-text--dropcap" data-caps="initial"><span data-caps="initial">B</span><small>UYOUT SHOPS</small> are neck-deep in dry powder. Earlier this year the world’s private-equity firms were sitting on $1.9trn in unspent capital. This month three of the biggest, Blackstone, Carlyle and Hellman &amp; Friedman, reportedly agreed to pay $34bn for control of Medline, a supplier of medical equipment. It will be the biggest leveraged buyout since the global financial crisis of 2007-09 put paid to most such debt-fuelled acquisitions.<span data-ornament="ufinish">■</span></p><p class="article__footnote" data-test-id="Footnote">This article appeared in the Business section of the print edition under the headline "Dealing with abundance"</p><div class="layout-article-links layout-article-promo"><a class="ds-actioned-link ds-actioned-link--reuse-this-content" href="https://s100.copyright.com/AppDispatchServlet?publisherName=economist&amp;publication=economist&amp;title=Does%20the%20Medline%20mega-deal%20herald%20the%20return%20of%20giant%20buyouts%3F&amp;publicationDate=2021-06-12&amp;contentID=%2Fcontent%2Fufa2hirmj65q7u6020g58htl8pimm2ph&amp;type=A&amp;orderBeanReset=TRUE" target="_blank"><span>Reuse this content</span></a><a class="ds-actioned-link ds-actioned-link--the-trust-project" href="https://www.economist.com/about-the-economist"><span>The Trust Project</span></a></div></div></body></html>